Sagimet Biosciences (SGMT) Common Equity (2022 - 2026)
Sagimet Biosciences' Common Equity was $256.16 million in Q2 2026, up 96.8% from $130.16 million a year earlier and up 150.0% from the prior quarter.
Powered by 
Analysis
Sagimet Biosciences (SGMT) Common Equity (2022 - 2026) Analysis & Trends
At the end of FY2025, Common Equity at Sagimet Biosciences came in at $111.38 million, down 28.5% from FY2024.
- In earlier years, Common Equity was $155.81 million in FY2024 (+71.1%), $91.07 million in FY2023 and -$186.95 million in FY2022.
- The Q2 2026 figure marks the highest quarterly Common Equity in data going back to Q2 2022.
- Compared with a year earlier, Common Equity was higher in three of the last eight quarters, with growth averaging 12.7%.
- The best year-over-year quarter for Common Equity over five years was Q2 2026 (growth of 96.8%); the worst was Q3 2025 (a decline of 30.1%).
- Per Business Quant data, SGMT's Common Equity in the three quarters before Q2 2026 was $102.46 million (Q1 2026), $111.38 million (Q4 2025) and $119.26 million (Q3 2025).
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Common Equity (Qtr) |
|---|---|---|---|---|---|
| 1 | Eli Lilly | 1,264.65 Bn | 1,238.27 Bn | 20.46 Bn | 40.27 Bn |
| 2 | Johnson & Johnson | 677.74 Bn | 597.60 Bn | 17.30 Bn | 81.53 Bn |
| 3 | AbbVie | 517.10 Bn | 485.11 Bn | 13.12 Bn | -4.58 Bn |
| 4 | Merck | 362.23 Bn | 325.17 Bn | 13.19 Bn | 44.95 Bn |
| 5 | Novartis Ag | 315.90 Bn | 276.16 Bn | 11.24 Bn | 41.95 Bn |
| 6 | Astrazeneca | 289.40 Bn | 266.24 Bn | 12.86 Bn | 50.37 Bn |
| 7 | Amgen | 249.90 Bn | 201.56 Bn | 7.58 Bn | 14.35 Bn |
| 8 | Gilead Sciences | 209.15 Bn | 184.26 Bn | 6.73 Bn | 13.04 Bn |
| 9 | Pfizer | 165.88 Bn | 113.23 Bn | 12.56 Bn | 89.30 Bn |
| 10 | Sagimet Biosciences | 569.92 Mn | -4.57 Mn | - | 256.16 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 256.16 Mn |
| Mar 31, 2026 | 102.46 Mn |
| Dec 31, 2025 | 111.38 Mn |
| Sep 30, 2025 | 119.26 Mn |
| Jun 30, 2025 | 130.16 Mn |
| Mar 31, 2025 | 138.99 Mn |
| Dec 31, 2024 | 155.81 Mn |
| Sep 30, 2024 | 170.68 Mn |
| Jun 30, 2024 | 183.29 Mn |
| Mar 31, 2024 | 190.02 Mn |
| Dec 31, 2023 | 91.07 Mn |
| Sep 30, 2023 | 97.88 Mn |
| Jun 30, 2023 | -198.41 Mn |
| Mar 31, 2023 | -192.70 Mn |
| Dec 31, 2022 | -186.95 Mn |
| Sep 30, 2022 | -180.55 Mn |
| Jun 30, 2022 | -173.42 Mn |
API Access
Sagimet Biosciences Common Equity API
Pull this series into your own models, spreadsheets and apps with the Business Quant
Historical Metrics API. The request below matches the chart above — change the
frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.
https://data.businessquant.com/historic?slug=common-equity&ticker=SGMT&period=max&api_key=YOUR_API_KEYimport requests
url = "https://data.businessquant.com/historic"
params = {"slug": "common-equity", "ticker": "SGMT", "period": "max", "api_key": "YOUR_API_KEY"}
data = requests.get(url, params=params).json()const res = await fetch("https://data.businessquant.com/historic?slug=common-equity&ticker=SGMT&period=max&api_key=YOUR_API_KEY");
const data = await res.json();